Predictive Molecular Tumour Testing: What Are the Obstacles between Bench and Bedside?

Download
Citations
Altmetric
Author
Mileshkin, L; Shah, B; Michael, MDate
2012Source Title
Chemotherapy Research and PracticePublisher
Hindawi LimitedAffiliation
Medical EducationMedicine and Radiology
Metadata
Show full item recordDocument Type
Journal ArticleCitations
Mileshkin, L., Shah, B. & Michael, M. (2012). Predictive Molecular Tumour Testing: What Are the Obstacles between Bench and Bedside?. Chemother Res Pract, 2012, pp.838509-. https://doi.org/10.1155/2012/838509.Access Status
Open AccessOpen Access at PMC
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3359779Abstract
There have been many exciting new breakthroughs in understanding tumour biology. This has opened up the possibility of personalized treatment for people with certain tumours. The epidermal growth factor receptor (EGFR) and K-ras are two such targets that can help classify tumours on a molecular basis and guide treatment decisions. However, there are still questions about how best to implement new molecular tests like these to characterize tumours in clinical practice. Potential obstacles include availability of good quality tissue specimens, access to the right test, and consensus about interpretation, funding, and availability. In this paper, we review these issues, by discussing these two examples in detail and suggest some actions for addressing potential barriers.
Export Reference in RIS Format
Endnote
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
Refworks
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References